Login
Search
Search
0 Dates
2026
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
CPC 2026
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Refining risk in Pulmonary Arterial Hypertension: should we look to the right heart?
Session:
Sessão de Posters 33 - Cardiopatia congénita e hipertensão pulmonar: da evidência à ação
Speaker:
Adriana Henriques Silva
Congress:
CPC 2026
Topic:
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
Theme:
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
Subtheme:
21.2 Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure – Epidemiology, Prognosis, Outcome
Session Type:
Posters Eletrónicos
FP Number:
---
Authors:
Adriana Silva; Sofia Alegria; Filipa Ferreira; Ana Cláudia Vieira; Bárbara Ferreira; Débora Repolho; João Luz; Otília Simões; Hélder Pereira
Abstract
<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri">Background: Risk stratification is essential in pulmonary arterial hypertension (PAH), guiding both prognosis and therapeutic decisions. Current models are mainly based on clinical and functional variables such as WHO functional class, six-minute walk distance, and natriuretic peptides. However, these tools do not include right ventricular (RV) function, an important determinant of outcome in PAH. Echocardiographic parameters reflecting RV contractility and ventriculo-arterial coupling may refine risk assessment.</span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri">Purpose: To evaluate the prognostic performance of echocardiographic indices of RV systolic function in group 1 PAH.</span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri">Methods: Seventy-eight patients with PAH were followed for 12 months in a referral center. The composite endpoint included death, lung transplantation or initiation of intravenous prostanoids. Baseline echocardiography evaluated included tricuspid annular plane systolic excursion (TAPSE), systolic pulmonary artery pressure (sPAP), TAPSE/sPAP and TAPSE/tricuspid regurgitant velocity (TRV) ratios, tricuspid annular systolic velocity (tricuspid S′), right atrial (RA) area, and tricuspid regurgitation (TR) severity. Prognostic performance was assessed with Cox regression and ROC analyses; optimal thresholds were derived using the Youden index. Survival distributions were compared using Kaplan–Meier. </span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri">Results: The mean age was 52 ± 17 years, 69% were female. WHO functional class III–IV was present in 79.5% of the cohort. Eleven patients (14%) reached the endpoint. </span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri">In univariate Cox analysis, lower TAPSE (HR 0.85, p = 0.018), S′ (HR 0.77, p = 0.039), TAPSE/TRV (HR 0.56, p = 0.037) and TAPSE/sPAP (HR 0.09, p = 0.064) were associated with events. </span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri">ROC analysis demonstrated good discriminative ability: TAPSE < 18 mm (AUC 0.738, sensibility 73%, specificity 70%); tricuspid S′ < 9 cm/s (AUC 0.747, sensibility 75%, specificity 71%); TAPSE/TRV < 3.7 mm·s/m (AUC 0.719, sensibility 70%, specificity 68%), TAPSE/sPAP < 0.25 mm/mmHg (AUC 0.710, sensibility 67%, specificity 70%).</span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri">The AUC-derived TAPSE/PSAP ratio cut-off separated the cohort into two prognostic groups, with the high-risk category showing significantly poorer survival (Log-Rank p=0.042) (Figure 1). </span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri">Conclusions: TAPSE, tricuspid S′, TAPSE/TRV, and TAPSE/sPAP were associated with adverse outcomes and exhibited moderate predictive accuracy. These simple, non-invasive measures may complement current clinical risk scores, refining prognostic stratification in PAH.</span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site